In this issue:
Dolutegravir discontinuation for adverse events
Intolerance to dolutegravir-containing combination ART
Emtricitabine/tenofovir/efavirenz for acute HIV infection
Smoking and cessation effects on HIV life expectancy
Dolutegravir concentrations and HIV-1-RNA decay in semen
Cytomegalovirus and Epstein-Barr virus during early HIV infection
Reducing HIV infection in people who inject drugs
Metrics to predict acute MI and all-cause mortality
Long-acting rilpivirine as potential PrEP
Systematic review and network meta-analysis of first-line ART
Please login below to download this issue (PDF)